Clinical cancer genomic profiling
D Chakravarty, DB Solit - Nature Reviews Genetics, 2021 - nature.com
Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Background Advanced prostate cancer remains one of the most common and deadly
cancers, despite advances in treatment options. Immunotherapy has provided little benefit to …
cancers, despite advances in treatment options. Immunotherapy has provided little benefit to …
Androgen receptor activity in T cells limits checkpoint blockade efficacy
Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …
tumour immunity in solid tumours. In patients with advanced prostate cancer …
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
Abstract B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune
checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early …
checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early …
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
R García-Vílchez, AM Añazco-Guenkova, S Dietmann… - Molecular cancer, 2023 - Springer
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the
development of many cancers; however, little is known about the role and implications of …
development of many cancers; however, little is known about the role and implications of …
Cathepsin K regulates the tumor growth and metastasis by IL-17/CTSK/EMT axis and mediates M2 macrophage polarization in castration-resistant prostate cancer
N Wu, YZ Wang, KK Wang, BQ Zhong, YH Liao… - Cell death & …, 2022 - nature.com
A common stage of advanced prostate cancer is castration-resistant prostate cancer
(CRPC), greater understanding of which is required in order to address and solve the …
(CRPC), greater understanding of which is required in order to address and solve the …
Is there a role for immunotherapy in prostate cancer?
A Rizzo, V Mollica, A Cimadamore, M Santoni… - Cells, 2020 - mdpi.com
In the last decade, immunotherapy has revolutionized the treatment landscape of several
hematological and solid malignancies, reporting unprecedented response rates …
hematological and solid malignancies, reporting unprecedented response rates …
Complexities of prostate cancer
Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
T Powles, KC Yuen, S Gillessen, EE Kadel Iii… - Nature medicine, 2022 - nature.com
Early clinical data indicate that some patients with castration-resistant prostate cancer may
benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. The …
benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. The …
Immune checkpoint inhibitors in prostate cancer
Simple Summary Metastatic prostate cancer is an incurable disease with limited treatment
options. Immunotherapy has demonstrated significant success in multiple cancer types but …
options. Immunotherapy has demonstrated significant success in multiple cancer types but …